We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
05 Sep 2020 - 09 Sep 2020
Virtual Venue

Biomarker Data Improves Risk Prediction for Pancreatic Cancer

By LabMedica International staff writers
Posted on 07 May 2020
Print article
Image: Histopathological micrograph of pancreatic adenocarcinoma arising in the pancreas head region (Photo courtesy of KGH).
Image: Histopathological micrograph of pancreatic adenocarcinoma arising in the pancreas head region (Photo courtesy of KGH).
Pancreatic cancer risk prediction models based on clinical factors may be refined and improved by bringing in other types of data, including germline genetic risk variant and blood-based biomarker data.

Pancreatic cancer is the third leading cause of cancer death in the USA, and 80% of patients present with advanced, incurable disease. Risk markers for pancreatic cancer have been characterized, but combined models are not used clinically to identify individuals at high risk for the disease.

A team of scientists led by those at the Harvard T.H. Chan School of Public Health (Boston, MA, USA) used a nested case-control approach, and brought together genetic, clinical, and other data for 500 individuals with primary pancreatic adenocarcinoma and 1,091 matched control individuals, enrolled through four prospective studies, using these data to develop several pancreatic cancer risk models based on clinical data alone, genetic and clinical factors, or genetic, clinical, and biomarker data.

Genomic DNA was extracted from peripheral blood leucocytes of cohort participants. Details on genotyping, variant imputation, and quality control procedures were previously reported. Circulating levels of proinsulin (pmol/L), adiponectin (mg/mL), interleukin-6 (IL-6; pg/mL), and branched-chain amino acids (BCAAs; mmol/L) were measured and represent four major categories of circulating markers related to pancreatic cancer risk (insulin resistance, adipokines, inflammation, and peripheral tissue catabolism, respectively). The team dichotomized circulating adiponectin with a cut off of 4.4 mg/mL).

When the team applied those models to almost 1,000 more cases or controls followed for up to 10 years, it found that the integrated model provided the most accurate pancreatic risk prediction, surpassing risk estimates done using clinical data without genetic or blood biomarker insights. Model discrimination showed an area under ROC curve of 0.62 via cross-validation. The final integrated model identified 3.7% of men and 2.6% of women who had at least three times greater than average risk in the ensuing 10 years. Individuals within the top risk percentile had a 4% risk of developing pancreatic cancer by age 80 years and 2% 10-year risk at age 70 years.

The authors wrote that because all of their subjects were enrolled in prospective cohorts, all risk factor data and circulating markers were measured before the cases' diagnosis of pancreatic cancer, faithfully recapitulates the situation faced by primary care physicians, where decisions related to disease screening are made in the prediagnostic setting using data collected in the several years prior to cancer diagnosis.

Peter Kraft, PhD, a Professor of Epidemiology and senior author of the study, said, “Like most cancers, pancreatic cancer is multifactorial. The more we are able to combine information from multiple domains, the better we will become at identifying those who could benefit from screening. These factors have been investigated individually and in this study, we wanted to examine the combined effect of clinical factors, common genetic predisposition variants, and circulating biomarkers.” The study was published on April 22, 2020 in the journal Cancer Epidemiology, Biomarkers, and Prevention.

Related Links:
Harvard T.H. Chan School of Public Health

Print article


Molecular Diagnostics

view channel
Image: The NovaSeq 6000 Sequencing System offers high-throughput sequencing across a broad range of applications (Photo courtesy of Illumina).

Somatic Evolution Identified in Non-Neoplastic IBD-Affected Colon

Inflammatory bowel disease (IBD) is a debilitating disease characterized by repeated flares of intestinal inflammation. The two major subtypes of IBD, Crohn’s disease (CD) and ulcerative colitis (UC) are... Read more

Industry News

view channel
Image: ChemWell RPR Analyzer (Photo courtesy of Awareness Technology, Inc.)

Awareness Technology Announces ChemWell RPR Analyzer - The Most Significant Innovation in Syphilis Testing in Last 30 Years

Awareness Technology, Inc. (Palm City, FL, USA) has announced the most significant innovation in syphilis testing in the last 30 years with the launch of the ChemWell RPR automated nontreponemal analyzer... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.